Current Report Filing (8-k)
February 21 2020 - 4:47PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(D)
of the Securities Exchange Act of 1934
February 20, 2020
Date of report (Date of earliest event reported)
Agile Therapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
001-36464
|
23-2936302
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
101 Poor Farm Road
Princeton, New Jersey
(Address of principal executive offices)
|
08540
(Zip Code)
|
Registrant's telephone number, including
area code (609) 683-1880
(Former name or former address, if changed
since last report)
|
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.0001 per share
|
AGRX
|
The Nasdaq Capital Market
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
On February 21, 2020, Agile
Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting
Agreement”) with RBC Capital Markets, LLC, William Blair & Company, L.L.C. and Oppenheimer & Co. Inc., as
representatives of the several underwriters named therein (the “Underwriters”), relating to the issuance and sale
of 15,000,000 shares (the “Shares”) of the Company’s common stock to the Underwriters (the
“Offering”). The Shares were sold at a price to the public of $3.00 per Share and were purchased by the
Underwriters from the Company at a price of $2.82 per Share. The Company also granted the Underwriters a 30-day option to
purchase up to 2,250,000 additional shares of its common stock. The net proceeds to the Company from the Offering, excluding
any exercise by the Underwriters of their 30-day option to purchase additional shares, are expected to be approximately
$42.1 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the
Company.
The Offering is expected to close on or
about February 25, 2020, subject to the satisfaction of customary closing conditions. The Underwriting Agreement contains customary
representations, warranties, covenants and agreements by the Company, indemnification obligations of the Company and the Underwriters,
including for liabilities under the Securities Act of 1933, as amended, other obligations of the parties and termination provisions.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement
and as of specific dates, and were solely for the benefit of the parties to the Underwriting Agreement.
The Offering is being made by means of a
written prospectus forming part of a shelf registration statement on Form S-3 (Registration Statement No. 333-228149),
previously filed by the Company with the Securities and Exchange Commission (the “SEC”) and declared effective by the
SEC on November 14, 2018, and a related prospectus supplement. The Underwriting Agreement is attached as Exhibit 1.1 hereto,
and the description of the terms of the Underwriting Agreement is qualified in its entirety by reference to such exhibit. A copy
of the opinion of Morgan, Lewis and Bockius LLP relating to the legality of the issuance and sale of the Shares in the Offering
is attached as Exhibit 5.1 hereto.
On February 20, 2020, the Company issued
a press release announcing that it had commenced the Offering. On February 21, 2020, the Company issued a press release announcing
the pricing of the Offering. Copies of these press releases are attached as Exhibits 99.1 and 99.2 hereto, respectively.
Neither the disclosures on this Form 8-K
nor the attached press releases shall constitute an offer to sell or the solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
|
Item
9.01.
|
Financial Statements and Exhibits.
|
(d)
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Agile Therapeutics, Inc.
|
|
|
|
|
|
|
Dated: February 21, 2020
|
By:
|
/s/ Alfred Altomari
|
|
Name:
|
Alfred Altomari
|
|
Title:
|
President and Chief Executive Officer
|
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agile Therapeutics (NASDAQ:AGRX)
Historical Stock Chart
From Apr 2023 to Apr 2024